Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study
Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study
Shannon Strom, Detlef Albrecht, Jessica Ailani, Alan M. Rapoport et al.
Citations
3 citations
Journal
CNS Drugs
Topics
Migraine and Headache Studies
Field-Weighted Citation Impact (FWCI)
1.16
article
Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study
Shannon Strom, Detlef Albrecht, Jessica Ailani, Alan M. Rapoport, Stewart J. Tepper, Louis Kirby
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
CNS DrugsVol. 38(12)
Institutions
University of California, Los Angeles (US), Georgetown University (US), Paradise Valley Community College (US), New England Institute for Neurology and Headache (US), Inspire Institute (US)